Ridgeback Biotherapeutics LP
https://www.ridgebackbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ridgeback Biotherapeutics LP
A Year Of Paxlovid - Where Is The Licensed Generic?
A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.
A Year Of Paxlovid - Where Is The Licensed Generic?
It’s been a year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir. Scrip looks at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023 as Hetero's version becomes the first with WHO Prequalification while two Chinese and a Korean company wait in the wings.
Merck Revenue Soars, Setting High Bar For Future Growth
With pharma sales up 13% in Q3, questions mount about investments in its pipeline to diversify beyond Keytruda and keep the momentum going after its top seller faces biosimilars in 2028.
Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice